Replies to post #1430 on Vascular Biogenics Ltd (VBLT)

[staccani]

No surprise ... there are many safe drugs which are not effective. Safety is a necessary condition but not sufficient to improve cancer patients survival and make VBL a multibillion USD company. I also think the new MFG facility and the start of prOC ph3 will not move PPS much.
rGBM Ph3 results will

[gr8db8]

I am somewhat surprised that the stock price did not increase by more than 3-5% (it's at negative 0.8% as I type this). But for long-term investors, daily/weekly price movements is not a big deal.

DSMC final recommendation is great. Topline data is in a few months. Ph3 prOC and facilities will not significantly move the needle. It will be the topline data and perhaps, a partnership announcement (if positive). But ultimately it will be the topline data, which will (hopefully) lead to FDA approval.